R elapse of the underlying disease is the commonest cause of treatment failure after allogeneic hemar r topoietic stem cell transplantation (allorHSCT) and is related to a poorer outcome. 1r3 Most relapses occur within the first two years of transplant. 2 Chronic myeloid leukemia (CML) in first chronic phase is among those with the lowest rates (10%r30%) of relapse. 4 On rare ocr r casions, an isolated extramedullary presentation is seen. 2, 3 In a large retrospective multicenter survey by Békassy et al, extramedullary relapse was reported in only 6 of 2753 (0.22%) grafted patients among the CML/myelodysplasr r tic subgroup. 3 In this report, we describe a rare presenting feature of postrtransplant relapse of CML and discuss the main therapeutic alternatives in this setting. an 18-year-old male underwent an allogeneic hematopoietic stem cell transplantation (allo-hsct) for chronic myeloid leukemia (cml) in the first late chronic phase. on day 132, he was readmitted to the hospital with nausea, vomiting and nodular lesions on endoscopy. a diagnosis of granulocytic sarcoma of the stomach was made. bone marrow cytogenetic analysis for the philadelphia chromosome and nested polymerase chain reaction for bcr-abl1 were both negative. immunosuppression was abruptly discon--tinued, and by day 180, all gastric lesions had completely disappeared. however, there were histologi--cal signs of graft-versus-host disease. the patient developed progressive anorexia and elevated hepatic enzymes, which prompted the reintroduction of cyclosporine. considering the risk of another relapse, imatinib mesylate (im) 600 mg/day was started. the patient´s condition improved, and there was no evi--dence of disease recurrence at 36 months after relapse. relapse of cml is the commonest cause of treat--ment failure after allo-hsct. on rare occasions, a localized extramedullary presentation is seen. unless properly treated, other extramedullary relapse sites and/or marrow infiltration usually occur. Withdrawal of immunosuppression, along with im therapy seems to be an acceptable approach in this setting.
CASE
tive (Ph+) CML in December 2003 and, since imatinib mesylate (IM) was not available as firstrline treatment, interferon alpha (IFNra) was used. Only a minor cytor r genetic response was observed after more than two years of treatment. As an HLArmatched unrelated male donor was available, an HSCT was performed. The conditionr r ing regimen consisted of busulfan, cyclophosphamide and antirthymocyte globulin. Cyclosporine and methotrexate were used for graftrversusrhost disease (GVHD) pror r phylaxis. Engraftment occurred at day 30. On day 63, he presented with a grade I GVHD of the skin, which was treated with oral steroids. After two weeks, ster r roids were progressively tapered off. Three months after transplant, cytogenetic analysis for the Ph chromosome and nested polymerase chain reaction (PCR) for BCRr ABL1 were both negative. On day 132, he was readmitr r ted to hospital due to a threerday history of vomiting and nausea. The physical examination was unremarkr r able. The complete blood count and chemistry profile were normal. Presuming occurrence of gastric GVHD, upper gastrointestinal endoscopy was performed. The exam revealed four erythematous round nodules on the gastric mucosa, with elevated borders and diamr r eters varying between 10 mm and 35 mm ( Figure 1 ). Biopsies were performed and a histopathological/imr r munohistochemical examination showed a diffuse infilr r trate of immature myeloid cells in the mucosa ( Figure  2 ). Fluorescent in situ hybridization (FISH) analysis was positive for BCRrABL1, consistent with a diagnor r sis of granulocytic sarcoma ( Figure 3 ). Bone marrow aspirate and biopsy showed no evidence of leukemia. Cytogenetic analysis and nested PCR remained negar r tive. There was no sign of active GVHD at that point, so immunosuppression was immediately stopped. After two weeks of drug discontinuation, a second endoscopy was performed. A significant regression of the two larger lesions and disappearance of the two smaller ones were observed . Given the response achieved, it was decided not to perform a donor lymphocyte infusion (DLI), and instead follow the remaining lesions with serial endosr r copies. On day 180, complete disappearance of the nodr r ules was observed. There were no signs of CML infilr r tration on histological evaluation, but signs of GVHD were present. The patient evolved with progressive anorexia and a significant increase in hepatic enzymes. Cyclosporine was reintroduced and, because of the risk of relapse, we decided to start with IM 600 mg/day. The patient´s condition improved, and subsequent endosr r copies showed no evidence of disease recurrence at 36 months after relapse. No major drug toxicity was notr r ed. He developed chronic limited GVHD of the skin, and cyclosporine was being tapered, but otherwise the patient was well. The patient was in ongoing complete molecular remission (as evidenced by realrtime quantir r tative PCR negativity for BCRrABL1 transcripts) at a followrup of 36 months after relapse.
DISCUSSION
Granulocytic sarcoma, also known as myeloid sarcoma or chloroma, is a localized extramedullary tumor mass consisting of immature cells of granulocytic lineage in different maturation steps. 5 When presenting as postr transplant relapse, it most often occurs before or conr r currently with the onset of marrow infiltration. 2 In the first case, a misdiagnosis of lymphoma is frequently made. 5, 6 In our patient, FISH analysis of the gastric mucosa lesions confirmed the CML origin of the infilr r trating cells. Detection of BCRrABL1 transcripts by PCR has a prominent role in the early prediction of fullrblown rer r lapse of CML. 7 In our case, PCR for BCRrABL1 was negative at day 90 and was not capable of predicting overt disease, which was noticed less than two months later. This suggests a greater likelihood of isolated exr r tramedullary relapse. We cannot rule out whether the patient had a gastric lesion prior to transplantation. The underlying disease may have remained subclinical until the postrtransplant period, wherein an unfavorr r able immunological background may have contributed to the occurrence of overt disease.
Granulocytic sarcomas can involve virtually any organ.
2,3 CML seems to have a tendency to relapse in bone, which in turn is associated with subsequent marr r row relapse and short survival. 2 Other organs, particur r larly the gastrointestinal tract, are much less frequently affected. 2, 3, 8, 9 A recent case series by Cunningham anar r lyzed 35 first clinical extramedullary CML relapses afr r ter HSCT. 2 In 24 of these cases, extramedullary sites were the first signs of relapse, at a median of 13 months postrHSCT, with or without simultaneous marrow rer r lapse. There were only two reported patients with gasr r trointestinal relapse, both of whom died. 8, 9 Most cases were treated with radiotherapy, and only half received chemotherapy. None of the cases studied reported use of IM. Thirty of the 35 patients died within 12 months of relapse.
Treatment of extramedullary relapse in CML has generally not resulted in long survival. 4 A single rer r lapse site is usually followed, within months, by other extramedullary relapses and/or overt leukemia, unless prompt and aggressive treatment is undertaken. 2, 10 Postrtransplant reports have varied in description of therapy details, and there does not seem to be a conr r sensus as to the best therapeutic approach in this setr r ting. 2, 3 Surgery or radiotherapy alone may be effective in local disease control, but do not affect survival. 10 Encouraging remission rates are seen with DLI.
11 At present, this is the standard frontrline approach for CML relapse after allografting, since it is capable of inducing longrterm molecular remissions and restorr r ing full donor chimerism.
11 However, there is some evidence that granulocytic sarcomas exhibit a poorer response to chemotherapy and to the graftrversusrleur r kemia (GVL) effect, probably due to specific biologic properties of the leukemic cells at extramedullary sites, including increased tissue invasion and adhesion abilir r ties. 12 Cells exhibiting tumor growth may, therefore, rer r quire longer exposure to treatment for complete eradir r cation. There are some reports of postrDLI extramedr r ullary relapse in the presence of continuous marrow remission, which suggests an uneven medullary and extramedullary GVL effect. 13 In a study by Chong et al, patients with extramedullary relapse of a variety of hematological malignancies appeared to respond to cyr r totoxic therapy but not to DLI.
14 While patients with chronic GVHD have a lower overall relapse risk, they may be more prone to delayed relapse at extramedulr r lary sites.
14 Moreover, a study by Raiola et al showed a probability of DLIrrelated mortality of 44% for unr r related donor transplants as compared to a 9% rate for fullyrmatched siblings, mainly attributable to postr DLI GVHD. 15 Relapse type was the major predictor of response: patients with accelerated phase or blast crisis exhibited a response rate of only 36% to DLI, as opposed to 100% in those in molecular relapse alone.
A simple strategy for treating postrtransplant rer r lapse of CML is discontinuing immunosuppressive GVHD prophylaxis so as to restore the GVL effect, but successes have been anecdotal in the literature. 16 As mentioned in our report, considering the favorable response attained by the patient while withdrawing immunosuppression, as well as the side effects of DLI reported in the literature, particularly in the unrelated donor transplant setting, we decided to withhold this procedure.
The advent of IM, a tyrosine kinase inhibitor of BCRrABL fusionrgenerpositive cells, has revolutionr r ized the treatment of CML, and has had some promr r ising results in the postrtransplant relapse scenario. 17 However, the finding of granulocytic sarcoma lesions, as in the patient reported here, implies occurrence of relapse in blast crisis, wherein responses to IM tend to be of short duration. In a series of 128 patients with CML relapse after allografting, only 22% of those in blast crisis achieved a complete cytogenetic response with IM, and there were no complete molecular rer r sponses in this group. 17 In a recent retrospective study of 16 cases of postr transplant relapse of CML, the response rate to IM as frontrline therapy at relapse, or as secondr or thirdr line therapy after failure of DLI and/or IFNrarwas as expected from treatment with DLI alone.
18 Fifteen patients achieved cytogenetic and molecular responses (75% obtained RTrPCR negativity), and the patient who had relapsed in blast crisis achieved ongoing complete molecular remission, after a followrup of 45 months, with combined therapy of IM and DLI. In all of these cases, IM showed an acceptable sidereffect pror r file, and no GVHD reaction was seen, nor did cases of prior GVHD worsen during treatment. Therefore, IM could be considered for firstrline therapy when DLI is not available or if the worrisome side effects of this pror r cedure are expected. In our case, the patient responded well to withdrawal of immunosuppression, as evidenced by serial endoscopies, and it seemed reasonable to keep him on maintenance therapy with IM (at a dose of 600 mg daily), since the risk of overt relapse was high.
In conclusion, a greater awareness of the possibility of postrHSCT extramedullary relapse of CML once suspicious symptoms or lesions are encountered, such as in our case, may allow early treatment of a potentialr r ly curable disease. Doseradjustment or discontinuation of immunosuppression, along with IM therapy, seems to be an acceptable approach in this setting. A better understanding of the nature, prognosis, and treatment options of this rare condition may help patients achieve longrlasting remissions. 
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